^
    Apply
    A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation (NCT05410145)
    Phase 1/2
    D3 Bio (Wuxi) Co., Ltd
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    08/03/2022
    Primary completion :
    09/01/2026
    Completion :
    09/01/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • pemetrexed • D3S-001